Endothelin Receptor Antagonists

Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN RECECPTORS.

Also Known As:

Endothelin Antagonists; Antagonist, Endothelin; Antagonist, Endothelin Receptor; Antagonists, Endothelin; Antagonists, Endothelin Receptor; Receptor Antagonist, Endothelin; Endothelin Antagonist; Endothelin Receptor Antagonist

Networked: 1189 relevant articles (151 outcomes, 228 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Endothelin Receptor Antagonists: 1189
      - Endothelin A Receptor Antagonists: 25
      - Endothelin B Receptor Antagonists: 2

Experts

1.	Dingemanse, Jasper: 28 articles (01/2021 - 04/2002)
2.	Rubin, Lewis J: 21 articles (01/2019 - 01/2002)
3.	Sitbon, Olivier: 17 articles (01/2020 - 07/2003)
4.	Sidharta, Patricia N: 16 articles (01/2021 - 03/2012)
5.	Galiè, Nazzareno: 15 articles (01/2019 - 04/2003)
6.	Simonneau, Gérald: 15 articles (01/2019 - 07/2003)
7.	Webb, David J: 14 articles (01/2021 - 08/2002)
8.	Humbert, Marc: 13 articles (07/2020 - 12/2004)
9.	Hoeper, Marius M: 13 articles (01/2020 - 10/2005)
10.	Hoeper, M M: 12 articles (10/2016 - 03/2002)

Related Diseases

1.	Pulmonary Arterial Hypertension 01/01/2021 - "To evaluate the efficacy of endothelin receptor antagonists (ERAs) in pulmonary arterial hypertension. " 06/01/2016 - "Endothelin receptor antagonists (ERAs) have been shown to improve the prognosis of patients with pulmonary arterial hypertension (PAH). " 03/01/2016 - "Endothelin receptor antagonists have been shown to improve exercise tolerance and survival in adult patients with pulmonary arterial hypertension. " 02/28/2013 - "To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. " 07/08/2009 - "To evaluate the efficacy of endothelin receptor antagonists in pulmonary arterial hypertension. "
2.	Pulmonary Hypertension 02/01/2006 - "Endothelin receptor antagonists have been shown to be effective for long-term management of pulmonary hypertension. " 04/01/1995 - "This study investigated the pharmacologic effect of endothelin receptor antagonists on cardiopulmonary hemodynamic variables in a beagle model of pulmonary hypertension. " 11/03/2017 - "The endothelin receptor antagonist is among the most effective agents for pulmonary hypertension. " 08/18/2016 - "Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants." 11/24/2014 - "The 6-min walking distance is often used for assessing the exercise capacity under the treatment with an endothelin receptor antagonist (ERA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). "
3.	Hypertension (High Blood Pressure) 03/01/2010 - "In preclinical studies, endothelin receptor antagonists were effective in treating hypertension (particularly with endothelial dysfunction) and CKD. " 03/01/2012 - "Finally, studies of endothelin antagonists for treatment of hypertension will be summarized. " 11/01/2010 - "DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension." 10/24/2009 - "A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial." 01/01/2023 - "A recent clinical trial for resistant hypertension published in The Lancet may yet herald a new era for endothelin receptor antagonists into the clinical mainstream."
4.	Systemic Scleroderma (Systemic Sclerosis) 12/11/2012 - "Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients." 02/01/2011 - "Endothelin receptor antagonists as disease modifiers in systemic sclerosis." 01/01/2005 - "Accordingly, new class of drugs, endothelin receptor antagonists have been introduced for treatment of patients with systemic sclerosis. " 01/01/2011 - "The purpose of this paper is to summarize the published studies and case reports evaluating the efficacy of endothelin receptor antagonists in the treatment of Raynaud's phenomenon and digital ulcers associated with systemic sclerosis." 06/01/2011 - "diabetes mellitus, systemic sclerosis) and the use of endothelin antagonists in these patient groups may yield improved outcomes."
5.	digital ulcers 01/01/2013 - "Endothelin receptor antagonists and scleroderma related digital ulcers." 01/01/2011 - "The purpose of this paper is to summarize the published studies and case reports evaluating the efficacy of endothelin receptor antagonists in the treatment of Raynaud's phenomenon and digital ulcers associated with systemic sclerosis." 11/24/2014 - "Endothelin receptor antagonists (ETRAs) are approved for the treatment of pulmonary hypertension and scleroderma-related digital ulcers. " 01/01/2011 - "Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis." 12/01/2004 - "Treatment with the endothelin receptor antagonist bosentan may be effective in preventing new digital ulcers and improving hand function in patients with SSc."

Related Drugs and Biologics

1.	Bosentan (Tracleer)
2.	Endothelins (Endothelin)
3.	Prostaglandins
4.	Sildenafil Citrate (Viagra)
5.	Type 5 Cyclic Nucleotide Phosphodiesterases
6.	Epoprostenol (Prostacyclin)
7.	macitentan
8.	Phosphodiesterase 5 Inhibitors
9.	Phosphodiesterase Inhibitors
10.	Endothelin-1 (Endothelin 1)

Related Therapies and Procedures

1.	Therapeutics
2.	Heart Transplantation (Grafting, Heart)
3.	Oral Administration
4.	Liver Transplantation
5.	Molecular Targeted Therapy